phase iii trials of tolebrutinib in relapsing-remitting and progressive ms
Published 3 years ago • 511 plays • Length 2:20Download video MP4
Download video MP3
Similar videos
-
2:28
tolebrutinib reduces new mri lesions in highly active relapsing ms
-
2:22
long-term safety and efficacy of tolebrutinib for relapsing multiple sclerosis
-
3:26
phase iii ultimate i & ii update: ublituximab versus teriflunomide in relapsing ms
-
4:22
btk inhibitors in treating the spectrum of ms
-
1:50
btk inhibitors for ms treatment: what do the recent trial readouts mean for the field?
-
3:41
review of btk inhibition in ms
-
0:38
assessing remibrutinib in patients with relapsing ms
-
48:33
btk inhibitors for ms: progress in the development of an emerging therapeutic approach
-
1:43
progressive ms: emerging treatments
-
2:22
btk inhibitors for multiple sclerosis: progressive disease and de-escalation
-
3:26
an update on research in btk inhibitors for the treatment of ms
-
1:15
the safety and efficacy of evobrutinib in multiple sclerosis
-
4:39
stephen l. hauser, md: fenebrutinib and btk inhibiton in progressive ms
-
10:57
masitinib for multiple sclerosis-phase iib/iii trial results
-
1:07
targeting the innate immune system with btk inhibitors to treat progressive ms
-
1:06
clinical trials of btk inhibitors in ms
-
1:27
btk inhibitors gain ground in ms
-
3:06
potential of evobrutinib to target progressive ms
-
6:03
changes in the ms treatment landscape over the last 2 years